Nienke R. Biermasz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nienke R. Biermasz has a total of 428 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Martin Pereira
Department of Endocrinology and Metabolism, Amsterdam University Medical Center, Amsterdam, the Netherlands
25 shared publications - Wouter Ralph van Furth
Department of Neurosurgery, University Neurosurgical Center Holland, Leiden University Medical Center , Leiden, ZA 2333
25 shared publications - Iris Catharina Maria Pelsma
Leiden University Medical Center
18 shared publications - Marco Johanna Theodorus Verstegen
Department of Neurosurgery, University Neurosurgical Center Holland, Leiden University Medical Center , Leiden, ZA 2333
14 shared publications - Amir H. Zamanipoor Najafadabadi
Department of Ophthalmology, Leiden University Medical Center , Leiden, ZA 2333
13 shared publications - Friso de Vries
Department of Medicine, Division of Endocrinology and Center for Endocrine Tumors Leiden (CETL), Leiden University Medical Center, Leiden, The Netherlands
11 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Bioscientifica in Endocrine Connections
Growth Hormone excess in patients with McCune-Albright Syndrome: a literature systematic review and pooled data analysis
Growth hormone (GH) excess in Fibrous dysplasia/McCune-Albright (FD/MAS) syndrome has detrimental effects on Craniofacial fibrous dysplasia (CFD), leading to visual and hearing impairment, therefore early diagnosis and treatment is paramount. Current data on early clinical manifestations and management is scarce. A systematic search retrieved studies reporting diagnosis and management of GH excess in FD/MAS. 184 patients from 101 publications were included. Clinical presentation ranged from asymptomatic to clinically overt GH excess. Craniofacial fibrous dysplasia was present in 174 patients (98.9%), with progressive facial asymmetry being the most reported clinical sign. Median age at FD/MAS diagnosis was 12 years (IQR 6–25), whereas in most patients GH excess was diagnosed in the third decade (median 22 years; IQR 11–33). GH was unsuppressed on suppression testing in 64 (83.1%), while 13 (16.9%) had a paradoxical increase. Four patients had unsuppressed GH despite normal IGF1 levels. Pituitary imaging revealed a normal gland in 20.5%, diffuse pituitary hyperplasia in 9.6%, and a pituitary adenoma in 69.9%. Hyperprolactinemia was the most common associated endocrinopathy (72.1%). Medical therapy was the most frequent first-line treatment. Surgery was limited by craniofacial fibrous dysplasia, and radiotherapy poses a risk of malignant transformation in FD. Clinicians should maintain a high index of suspicion for GH excess, particularly, though not exclusively, in patients with craniofacial fibrous dysplasia progression. Systematic reporting in dedicated registries, rather than in isolated case reports, is essential to improve understanding and management.
- 4 November 2026
- Published by Bioscientifica in Endocrine Connections
Open AccessGrowth Hormone excess in patients with McCune-Albright Syndrome: a literature systematic review and pooled data analysis
Growth hormone (GH) excess in Fibrous dysplasia/McCune-Albright (FD/MAS) syndrome has detrimental effects on Craniofacial fibrous dysplasia (CFD), leading to visual and hearing impairment, therefore early diagnosis and treatment is paramount. Current data on early clinical manifestations and management is scarce. A systematic search retrieved studies reporting diagnosis and management of GH excess in FD/MAS. 184 patients from 101 publications were included. Clinical presentation ranged from asymptomatic to clinically overt GH excess. Craniofacial fibrous dysplasia was present in 174 patients (98.9%), with progressive facial asymmetry being the most reported clinical sign. Median age at FD/MAS diagnosis was 12 years (IQR 6–25), whereas in most patients GH excess was diagnosed in the third decade (median 22 years; IQR 11–33). GH was unsuppressed on suppression testing in 64 (83.1%), while 13 (16.9%) had a paradoxical increase. Four patients had unsuppressed GH despite normal IGF1 levels. Pituitary imaging revealed a normal gland in 20.5%, diffuse pituitary hyperplasia in 9.6%, and a pituitary adenoma in 69.9%. Hyperprolactinemia was the most common associated endocrinopathy (72.1%). Medical therapy was the most frequent first-line treatment. Surgery was limited by craniofacial fibrous dysplasia, and radiotherapy poses a risk of malignant transformation in FD. Clinicians should maintain a high index of suspicion for GH excess, particularly, though not exclusively, in patients with craniofacial fibrous dysplasia progression. Systematic reporting in dedicated registries, rather than in isolated case reports, is essential to improve understanding and management.
- 16 September 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 195 (4) , R109-R118
Genetic testing and reporting: what the endocrinologists should know and can expect (joint position paper of the ENDO-ERN)
Over the last decade, next-generation sequencing (NGS) has become an essential tool for diagnostic DNA testing in human genetics. To improve the understanding of available genetic testing strategies and to facilitate the request of genetic testing in daily endocrine practice, clinical and laboratory experts in the field have summarized the major issues which should be known and considered. In this joint position paper of the ENDO-ERN, the roles and responsibilities of the healthcare professionals involved in the diagnostic workflow are described, and the major issues concerning genetic testing workflows are overviewed. These issues encompass all relevant steps, including test request and pre-analytical procedures, laboratory and data processing workflows, quality assurance, and reporting. As NGS procedures result in an increasing number of variants of unknown significance and incidental findings, these aspects are addressed as well. Accompanied by illustrations of the genetic diagnostic workflow and of concise reports for a fast orientation about the major aspects of genetic testing, this joint paper should support the healthcare professionals during a request for genetic testing.
- 16 September 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 195 (4) , R109-R118
Genetic testing and reporting: what the endocrinologists should know and can expect (joint position paper of the ENDO-ERN)
Over the last decade, next-generation sequencing (NGS) has become an essential tool for diagnostic DNA testing in human genetics. To improve the understanding of available genetic testing strategies and to facilitate the request of genetic testing in daily endocrine practice, clinical and laboratory experts in the field have summarized the major issues which should be known and considered. In this joint position paper of the ENDO-ERN, the roles and responsibilities of the healthcare professionals involved in the diagnostic workflow are described, and the major issues concerning genetic testing workflows are overviewed. These issues encompass all relevant steps, including test request and pre-analytical procedures, laboratory and data processing workflows, quality assurance, and reporting. As NGS procedures result in an increasing number of variants of unknown significance and incidental findings, these aspects are addressed as well. Accompanied by illustrations of the genetic diagnostic workflow and of concise reports for a fast orientation about the major aspects of genetic testing, this joint paper should support the healthcare professionals during a request for genetic testing.
- 28 August 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 195 (3) , S23-S35
Dietary interventions and vitamin D3 replacement in pituitary tumors: a systematic review
Objectives: Pituitary neuroendocrine tumors (PitNETs) cause hormonal imbalances that impair metabolic health and quality of life (QoL). Dietary interventions may mitigate these comorbidities. This review evaluated the effectiveness of dietary strategies in improving disease-related metabolic and bone outcomes in patients with PitNETs. Design: Systematic review of interventional and observational studies on dietary interventions in acromegaly, Cushing's disease (CD), prolactinomas, and hypopituitarism (HP). Methods: A systematic search was performed on January 20, 2026. Eligible studies assessed dietary interventions targeting metabolic or bone-related outcomes. Risk of bias was evaluated using ROBINS-I and the Newcastle–Ottawa Scale. Extracted outcomes included dietary intake, body composition, metabolic parameters, biochemical control, and bone health. Results: Of 2256 screened records, 8 studies (355 participants) met the inclusion criteria, including 5 interventional and 3 observational studies. In acromegaly, an isocaloric very-low-carbohydrate ketogenic diet (VLCKD) reduced insulin-like growth factor 1 (IGF-I) levels. In CD, VLCKD and energy-restricted diets (ERD) improved BMI and metabolic parameters. In prolactinoma, ERD combined with increased physical activity improved weight and biochemical control. In HP, ERD with increased physical activity and sibutramine improved body composition and metabolic outcomes. Vitamin D replacement reduced vertebral fracture risk in acromegaly and improved insulin sensitivity and lipid levels in CD. Conclusions: Evidence on dietary strategies for PitNET management is limited. Low-carbohydrate diet and ERD may improve adverse metabolic comorbidities, while vitamin D3 replacement shows potential benefits for insulin sensitivity in CD and fracture risk in acromegaly. Larger randomized trials are needed to confirm effects on disease control, comorbidities, and QoL.
- 28 August 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 195 (3) , S23-S35
Dietary interventions and vitamin D3 replacement in pituitary tumors: a systematic review
Objectives: Pituitary neuroendocrine tumors (PitNETs) cause hormonal imbalances that impair metabolic health and quality of life (QoL). Dietary interventions may mitigate these comorbidities. This review evaluated the effectiveness of dietary strategies in improving disease-related metabolic and bone outcomes in patients with PitNETs. Design: Systematic review of interventional and observational studies on dietary interventions in acromegaly, Cushing's disease (CD), prolactinomas, and hypopituitarism (HP). Methods: A systematic search was performed on January 20, 2026. Eligible studies assessed dietary interventions targeting metabolic or bone-related outcomes. Risk of bias was evaluated using ROBINS-I and the Newcastle–Ottawa Scale. Extracted outcomes included dietary intake, body composition, metabolic parameters, biochemical control, and bone health. Results: Of 2256 screened records, 8 studies (355 participants) met the inclusion criteria, including 5 interventional and 3 observational studies. In acromegaly, an isocaloric very-low-carbohydrate ketogenic diet (VLCKD) reduced insulin-like growth factor 1 (IGF-I) levels. In CD, VLCKD and energy-restricted diets (ERD) improved BMI and metabolic parameters. In prolactinoma, ERD combined with increased physical activity improved weight and biochemical control. In HP, ERD with increased physical activity and sibutramine improved body composition and metabolic outcomes. Vitamin D replacement reduced vertebral fracture risk in acromegaly and improved insulin sensitivity and lipid levels in CD. Conclusions: Evidence on dietary strategies for PitNET management is limited. Low-carbohydrate diet and ERD may improve adverse metabolic comorbidities, while vitamin D3 replacement shows potential benefits for insulin sensitivity in CD and fracture risk in acromegaly. Larger randomized trials are needed to confirm effects on disease control, comorbidities, and QoL.
- Open Access
- 13 August 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
The Dutch prolactinoma cohort studies: cross-sectional analysis of females focusing on the patient's perspective
Purpose: To assess the results of patient-reported outcome measures (PROMs) by disease activity in a national cohort of females with a prolactinoma. Methods: Females with prolactinoma included in the PRolaCT or ProlaC study were assessed cross-sectionally, comparing patients with active (prolactin above upper limit of normal [ULN]) and controlled (prolactin < ULN) disease. Disease and treatment characteristics were reported. Patients completed PROMs on symptoms (modified PRO-CTCAE), health-related quality of life (HR-QoL) (SF-36), anxiety and depressive symptoms (Hospital Anxiety and Depression Scale (HADS)), and disease burden (Leiden Bother and Needs Questionnaire for patients with Pituitary disease [LBNQ-Pituitary]). Results: A total of 450 females with a prolactinoma were included (active: n = 223, controlled: n = 227); most (97.0%) were treated with dopamine agonists (DAs). Fatigue was the most prevalent symptom in both patients with active and controlled disease (92.6%, and 86.4%, respectively) followed by concentration problems (79.0%, and 64.5%, respectively) (modified PRO-CTCAE, LBNQ-Pituitary). Anxiety and depressive symptoms were worse in patients with active compared to controlled disease (HADS-Anxiety: 8.0 ± 4.5 vs 6.4 ± 4.5 P < .001. HADS-Depression: 6.4 ± 5.0 vs 4.7 ± 4.4 P < .001). Disease burden was higher in patients with active compared to controlled disease (LBNQ-Pituitary: Total Bother 24.4 ± 22.9 vs 16.4 ± 17.9; P < .001). Conclusion: Females with a prolactinoma were most affected by fatigue and cognitive complaints. Although patients with active disease perceived more burden than patients with controlled disease, symptoms including fatigue and psychological and cognitive complaints were prevalent despite disease control. Therefore, improvement of treatment and rehabilitation strategies is needed.
- 13 August 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Open AccessThe Dutch prolactinoma cohort studies: cross-sectional analysis of females focusing on the patient's perspective
Purpose: To assess the results of patient-reported outcome measures (PROMs) by disease activity in a national cohort of females with a prolactinoma. Methods: Females with prolactinoma included in the PRolaCT or ProlaC study were assessed cross-sectionally, comparing patients with active (prolactin above upper limit of normal [ULN]) and controlled (prolactin < ULN) disease. Disease and treatment characteristics were reported. Patients completed PROMs on symptoms (modified PRO-CTCAE), health-related quality of life (HR-QoL) (SF-36), anxiety and depressive symptoms (Hospital Anxiety and Depression Scale (HADS)), and disease burden (Leiden Bother and Needs Questionnaire for patients with Pituitary disease [LBNQ-Pituitary]). Results: A total of 450 females with a prolactinoma were included (active: n = 223, controlled: n = 227); most (97.0%) were treated with dopamine agonists (DAs). Fatigue was the most prevalent symptom in both patients with active and controlled disease (92.6%, and 86.4%, respectively) followed by concentration problems (79.0%, and 64.5%, respectively) (modified PRO-CTCAE, LBNQ-Pituitary). Anxiety and depressive symptoms were worse in patients with active compared to controlled disease (HADS-Anxiety: 8.0 ± 4.5 vs 6.4 ± 4.5 P < .001. HADS-Depression: 6.4 ± 5.0 vs 4.7 ± 4.4 P < .001). Disease burden was higher in patients with active compared to controlled disease (LBNQ-Pituitary: Total Bother 24.4 ± 22.9 vs 16.4 ± 17.9; P < .001). Conclusion: Females with a prolactinoma were most affected by fatigue and cognitive complaints. Although patients with active disease perceived more burden than patients with controlled disease, symptoms including fatigue and psychological and cognitive complaints were prevalent despite disease control. Therefore, improvement of treatment and rehabilitation strategies is needed.
- Open Access
- 30 April 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 194 (5) , 694-714
Prolactinoma course and management in transgender women: case report and systematic review
Objective: Prolactinomas are the most common functioning pituitary neuroendocrine tumors (PitNETs). In transgender women, gender-affirming hormone therapy (GAHT) usually combines high doses of estrogen and anti-androgen therapy, both of which can elevate serum prolactin levels. Whether GAHT influences tumor behavior in patients with pre-existing prolactinomas remains unclear. Design and methods: Case report illustrating the clinical challenges in managing a prolactinoma in the context of GAHT initiation, combined with a systematic review of all published cases and available guidelines of GAHT in the prolactinoma context. Results: A 22-year-old female (46,XY; assigned male at birth) with untreated gender dysphoria and hypogonadism was diagnosed with a macroprolactinoma (39.9 mm; serum prolactin 285 × upper limit of normal (ULN)). Cabergoline therapy reduced prolactin levels to 27.3 × ULN within one year. Pituitary apoplexy with acute visual field and acuity deterioration required emergency transsphenoidal debulking. Two months postoperatively, prolactin levels were 8.6 × ULN with total hypopituitarism and small irresectable remnants. Initiation of estrogen therapy led to unexpected biochemical (128.4 × ULN) and radiological progression despite cabergoline reintroduction and dose escalation, necessitating estrogen withdrawal to stabilize the disease. Subsequent radiotherapy allowed safe estrogen reintroduction. To date, 24 prolactinomas in transgender women (including this case) have been reported, most diagnosed after GAHT initiation and lacking baseline prolactin data. Current clinical guidelines provide no specific recommendations for pituitary tumors in this population. Conclusions: GAHT initiation might induce rapid progression and concomitant dopamine-agonist resistance in residual macroprolactinoma. Individualized, multidisciplinary management is needed. Development of dedicated clinical guidelines is essential to combine tumor control with gender-affirming care.
- 30 April 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 194 (5) , 694-714
Open AccessProlactinoma course and management in transgender women: case report and systematic review
Objective: Prolactinomas are the most common functioning pituitary neuroendocrine tumors (PitNETs). In transgender women, gender-affirming hormone therapy (GAHT) usually combines high doses of estrogen and anti-androgen therapy, both of which can elevate serum prolactin levels. Whether GAHT influences tumor behavior in patients with pre-existing prolactinomas remains unclear. Design and methods: Case report illustrating the clinical challenges in managing a prolactinoma in the context of GAHT initiation, combined with a systematic review of all published cases and available guidelines of GAHT in the prolactinoma context. Results: A 22-year-old female (46,XY; assigned male at birth) with untreated gender dysphoria and hypogonadism was diagnosed with a macroprolactinoma (39.9 mm; serum prolactin 285 × upper limit of normal (ULN)). Cabergoline therapy reduced prolactin levels to 27.3 × ULN within one year. Pituitary apoplexy with acute visual field and acuity deterioration required emergency transsphenoidal debulking. Two months postoperatively, prolactin levels were 8.6 × ULN with total hypopituitarism and small irresectable remnants. Initiation of estrogen therapy led to unexpected biochemical (128.4 × ULN) and radiological progression despite cabergoline reintroduction and dose escalation, necessitating estrogen withdrawal to stabilize the disease. Subsequent radiotherapy allowed safe estrogen reintroduction. To date, 24 prolactinomas in transgender women (including this case) have been reported, most diagnosed after GAHT initiation and lacking baseline prolactin data. Current clinical guidelines provide no specific recommendations for pituitary tumors in this population. Conclusions: GAHT initiation might induce rapid progression and concomitant dopamine-agonist resistance in residual macroprolactinoma. Individualized, multidisciplinary management is needed. Development of dedicated clinical guidelines is essential to combine tumor control with gender-affirming care.
- Open Access
- 1 April 2026
- Published by Bioscientifica in Endocrine Connections
- Vol. 15 (4)
Mapping transition of care for rare endocrine conditions: findings from a cross-sectional survey by the Endo-ERN ToC Working Group
Background: Adolescents and young adults with rare endocrine conditions face significant challenges during the transition from paediatric to adult healthcare systems. Despite increasing awareness, unstructured transitional care is frequent across Europe and is linked to adverse health outcomes, reduced adherence, and loss to follow-up. Objective: This study aimed to map existing models of care and identify key barriers and needs that could inform the development of standardised tools and recommendations to support improved transition processes within the European Reference Network on Rare Endocrine Conditions (Endo-ERN) framework. Methods: A cross-sectional, web-based survey was developed and disseminated by the ‘Transition of Care’ Working Group. The questionnaire comprised 31 items across 10 thematic domains and targeted both Endo-ERN and non-affiliated centres. Responses were collected between January and March 2025. Statistical and qualitative thematic analyses were performed. Results: A total of 111 responses were analysed from 80 centres across 21 European countries. Findings revealed marked heterogeneity in transition models, use of protocols, and availability of psychological support. Only about half of the centres reported shared paediatric–adult visits, and over one-third lacked follow-up strategies. E-health tools were underutilised despite expressed interest. A significant proportion of participants reported limited access to transition coordinators and heterogeneous privacy and data protection practices, highlighting concerns regarding General Data Protection Regulation (GDPR) compliance. Conclusion: The study underscores the need for standardised, patient-centred models of transitional care for rare endocrine conditions across Europe. Findings will inform the creation of harmonised tools and protocols to guide multidisciplinary collaboration and improve long-term outcomes. Plain language summary: Young people with rare endocrine conditions often struggle when moving from child to adult healthcare. We surveyed centres across Europe and found large differences in how this process is organised. Our findings highlight the need for clearer plans, better coordination, and tools to support a safer and more consistent transition for all patients.
- 1 April 2026
- Published by Bioscientifica in Endocrine Connections
- Vol. 15 (4)
Open AccessMapping transition of care for rare endocrine conditions: findings from a cross-sectional survey by the Endo-ERN ToC Working Group
Background: Adolescents and young adults with rare endocrine conditions face significant challenges during the transition from paediatric to adult healthcare systems. Despite increasing awareness, unstructured transitional care is frequent across Europe and is linked to adverse health outcomes, reduced adherence, and loss to follow-up. Objective: This study aimed to map existing models of care and identify key barriers and needs that could inform the development of standardised tools and recommendations to support improved transition processes within the European Reference Network on Rare Endocrine Conditions (Endo-ERN) framework. Methods: A cross-sectional, web-based survey was developed and disseminated by the ‘Transition of Care’ Working Group. The questionnaire comprised 31 items across 10 thematic domains and targeted both Endo-ERN and non-affiliated centres. Responses were collected between January and March 2025. Statistical and qualitative thematic analyses were performed. Results: A total of 111 responses were analysed from 80 centres across 21 European countries. Findings revealed marked heterogeneity in transition models, use of protocols, and availability of psychological support. Only about half of the centres reported shared paediatric–adult visits, and over one-third lacked follow-up strategies. E-health tools were underutilised despite expressed interest. A significant proportion of participants reported limited access to transition coordinators and heterogeneous privacy and data protection practices, highlighting concerns regarding General Data Protection Regulation (GDPR) compliance. Conclusion: The study underscores the need for standardised, patient-centred models of transitional care for rare endocrine conditions across Europe. Findings will inform the creation of harmonised tools and protocols to guide multidisciplinary collaboration and improve long-term outcomes. Plain language summary: Young people with rare endocrine conditions often struggle when moving from child to adult healthcare. We surveyed centres across Europe and found large differences in how this process is organised. Our findings highlight the need for clearer plans, better coordination, and tools to support a safer and more consistent transition for all patients.
- Open Access
- 4 February 2026
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 87 (1) , 102490
Prevalence, risk factors and management of bone complications in Cushing's syndrome across Europe. Data from the European Registry on Cushing's syndrome (ERCUSYN)
- 4 February 2026
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 87 (1) , 102490
Open AccessPrevalence, risk factors and management of bone complications in Cushing's syndrome across Europe. Data from the European Registry on Cushing's syndrome (ERCUSYN)
- Open Access
- 14 November 2025
- Published by Bioscientifica in Endocrine Connections
- Vol. 14 (12)
Feasibility of transition research in pituitary disease using patient registries: a EuRREB secondary survey
Aim: Rare disease registries focusing on natural history provide an opportunity to understand the transition process for rare endocrine conditions, including pituitary diseases. This study aims to assess the feasibility of using the European Registry for Rare Endocrine & Bone Conditions (EuRREB) for transition research in pituitary disease and to establish basic clinical characteristics of transition-age pituitary patients managed at reference centers (RCs) within the European Reference Network for Rare Endocrine Conditions (Endo-ERN). Methods: Patients in the Core Registry of EuRREB aged between 14 and 24 years with a pituitary diagnosis were eligible for inclusion. Physicians were asked to fill out a secondary survey evaluating transition aspects. Descriptive statistics and non-parametric analysis (Kruskal–Wallis, Mann–Whitney) were used. Results: Of 106 eligible patients, 98 patients had a confirmed diagnosis. Secondary survey data were available for 79 patients (74%) across 6 RCs from 5 countries. 72/79 patients (91%) remained in active care, with a single patient lost or discharged from follow-up (each n = 1, 1.3%). 29/79 (36.7%) were already transferred to adult care. Transfer typically occurred at age 18 years and in a few patients up to 22 years. A documented transfer plan was reported for 11 patients (13.9%). Patient-reported outcomes were collected in ten patients (13.5%). Transition challenges were either care-related or patient-related. Conclusion: This study provides initial characterization of transition of care in rare pituitary diseases in Endo-ERN RCs, showing high follow-up but inconsistent use of plans, patient-reported outcome measures (PROMs), and documentation. Rare disease registries can act as a tool to understand the process and identify barriers.
- 14 November 2025
- Published by Bioscientifica in Endocrine Connections
- Vol. 14 (12)
Open AccessFeasibility of transition research in pituitary disease using patient registries: a EuRREB secondary survey
Aim: Rare disease registries focusing on natural history provide an opportunity to understand the transition process for rare endocrine conditions, including pituitary diseases. This study aims to assess the feasibility of using the European Registry for Rare Endocrine & Bone Conditions (EuRREB) for transition research in pituitary disease and to establish basic clinical characteristics of transition-age pituitary patients managed at reference centers (RCs) within the European Reference Network for Rare Endocrine Conditions (Endo-ERN). Methods: Patients in the Core Registry of EuRREB aged between 14 and 24 years with a pituitary diagnosis were eligible for inclusion. Physicians were asked to fill out a secondary survey evaluating transition aspects. Descriptive statistics and non-parametric analysis (Kruskal–Wallis, Mann–Whitney) were used. Results: Of 106 eligible patients, 98 patients had a confirmed diagnosis. Secondary survey data were available for 79 patients (74%) across 6 RCs from 5 countries. 72/79 patients (91%) remained in active care, with a single patient lost or discharged from follow-up (each n = 1, 1.3%). 29/79 (36.7%) were already transferred to adult care. Transfer typically occurred at age 18 years and in a few patients up to 22 years. A documented transfer plan was reported for 11 patients (13.9%). Patient-reported outcomes were collected in ten patients (13.5%). Transition challenges were either care-related or patient-related. Conclusion: This study provides initial characterization of transition of care in rare pituitary diseases in Endo-ERN RCs, showing high follow-up but inconsistent use of plans, patient-reported outcome measures (PROMs), and documentation. Rare disease registries can act as a tool to understand the process and identify barriers.
- Open Access
- 29 September 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (2) , 303-315
How to Define Success in Prolactinoma Treatment—A Systematic Review and Theoretical Framework
Purpose: As consensus regarding outcome sets for prolactinoma treatment evaluation is lacking, this study evaluated outcome parameters reported in the literature, and objective, clinically relevant outcome sets were proposed. Methods: A systematic review of studies up to February 2, 2024. Reported biochemical and radiological parameters; clinician-reported findings; patient-reported outcomes (PROs); and definitions of disease remission, control, and recurrence were extracted and placed into a clinical context. Subsequently, objective and clinically relevant definitions of clinical outcomes were proposed based on the findings, with comprehensive outcome sets to evaluate treatment success. Results: One hundred thirty-seven articles were included. Albeit ill-defined or subjective, 23 unique prolactin parameters and 73 unique radiological parameters were reported. Seventy articles included clinician-reported findings, and none reported PROs. Ultimately, 27 unique definitions of remission, 3 unique definitions of disease control, and 20 unique definitions of recurrence were reported. We propose 2 separate definitions for biochemical and clinical remission/recurrence—either evaluating prolactin levels only or including symptomology, gonadal function, and radiology. Integrated outcome quadrants were illustrated to objectively categorize treatment success by combining achievement of treatment goals with the occurrence of adverse effects. A 3-tier outcome set based on the Value-Based Healthcare principles is provided. Conclusion: Heterogeneity in reported outcome parameters using varying definitions hampers the comparison of prolactinoma treatment outcomes. This study proposes objective, easily applicable, and clinically relevant definitions of clinical outcomes and offers a comprehensive outcome set. These parameters enable comparison of outcomes across treatment modalities and medical centers to gain insight into this rare disease and improve prolactinoma care.
- 29 September 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (2) , 303-315
Open AccessHow to Define Success in Prolactinoma Treatment—A Systematic Review and Theoretical Framework
Purpose: As consensus regarding outcome sets for prolactinoma treatment evaluation is lacking, this study evaluated outcome parameters reported in the literature, and objective, clinically relevant outcome sets were proposed. Methods: A systematic review of studies up to February 2, 2024. Reported biochemical and radiological parameters; clinician-reported findings; patient-reported outcomes (PROs); and definitions of disease remission, control, and recurrence were extracted and placed into a clinical context. Subsequently, objective and clinically relevant definitions of clinical outcomes were proposed based on the findings, with comprehensive outcome sets to evaluate treatment success. Results: One hundred thirty-seven articles were included. Albeit ill-defined or subjective, 23 unique prolactin parameters and 73 unique radiological parameters were reported. Seventy articles included clinician-reported findings, and none reported PROs. Ultimately, 27 unique definitions of remission, 3 unique definitions of disease control, and 20 unique definitions of recurrence were reported. We propose 2 separate definitions for biochemical and clinical remission/recurrence—either evaluating prolactin levels only or including symptomology, gonadal function, and radiology. Integrated outcome quadrants were illustrated to objectively categorize treatment success by combining achievement of treatment goals with the occurrence of adverse effects. A 3-tier outcome set based on the Value-Based Healthcare principles is provided. Conclusion: Heterogeneity in reported outcome parameters using varying definitions hampers the comparison of prolactinoma treatment outcomes. This study proposes objective, easily applicable, and clinically relevant definitions of clinical outcomes and offers a comprehensive outcome set. These parameters enable comparison of outcomes across treatment modalities and medical centers to gain insight into this rare disease and improve prolactinoma care.
- Top Cited Papers
- 13 August 2025
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 21 (11) , 718-737
Consensus on acromegaly therapeutic outcomes: an update
The 15th Acromegaly Consensus Conference in September 2023 updated recommendations on therapeutic outcomes for acromegaly. Since the publication of medical management guidelines in 2018, new pharmacological agents and new treatment approaches have been developed. Fifty-two experts in the management of acromegaly reviewed the current literature and assessed changes in drug approvals, clinical practice standards and management. Current outcome goals were considered, with a focus on the effect of current and emerging somatostatin receptor ligands, the growth hormone receptor antagonist pegvisomant and the dopamine agonist cabergoline on biochemical control, clinical control, adenoma mass and surgical outcomes. Participants assessed factors that determine pharmacological choices, as well as the proposed use of each agent. Here, we present consensus recommendations highlighting how an evidence-based acromegaly management algorithm could be optimized in clinical practice.
- 13 August 2025
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 21 (11) , 718-737
Top Cited PapersConsensus on acromegaly therapeutic outcomes: an update
The 15th Acromegaly Consensus Conference in September 2023 updated recommendations on therapeutic outcomes for acromegaly. Since the publication of medical management guidelines in 2018, new pharmacological agents and new treatment approaches have been developed. Fifty-two experts in the management of acromegaly reviewed the current literature and assessed changes in drug approvals, clinical practice standards and management. Current outcome goals were considered, with a focus on the effect of current and emerging somatostatin receptor ligands, the growth hormone receptor antagonist pegvisomant and the dopamine agonist cabergoline on biochemical control, clinical control, adenoma mass and surgical outcomes. Participants assessed factors that determine pharmacological choices, as well as the proposed use of each agent. Here, we present consensus recommendations highlighting how an evidence-based acromegaly management algorithm could be optimized in clinical practice.